Date: 2014-10-14
Type of information: Distribution agreement
Compound: EnPresso® growth systems for microbial cell cultures
Company: BioSilta (UK) Sigma-Aldrich (USA - MO)
Therapeutic area: Technology - Services
Type agreement: distribution
Action mechanism: EnPresso B growth systems are series of reagent-based solutions that have been shown to increase recombinant protein yields from bacterial cultures by up to 100-fold and improve protein functionality. Products in the range include EnPresso B, EnPresso B Animal-free (certified free from animal-derived components), and EnPresso B Defined Nitrogen-free, used to significantly increase the yield of 15N-labeled proteins for NMR analysis.
EnPresso growth systems are based on BioSilta’s proprietary EnBase® technology which offers a novel approach to control the feeding, and thereby growth rate, of microbial cultures. This allows cultures to reach much higher cell densities compared to conventional growth media such as LB, TB or M9, resulting in higher yields of recombinant protein expressed under metabolically favorable conditions.
Disease:
Details: * On October 14, 2014, BioSilta, a developer of advanced, reagent-based microbial growth systems, announced the signing of a non-exclusive worldwide distribution agreement with Sigma-Aldrich®. Research scientists now have the option of ordering BioSilta’s EnPresso® growth systems for microbial cell cultures through global supplier Sigma-Aldrich.
Financial terms:
Latest news:
